RxDoctor Payments Data

Robert Jones, MD

Dermatology · Marrero, LANPI 1245454404

Payments from drug & device makers

$7,220in general payments, 2019–2025

Across 302 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Sanofi$698
  • Pfizer$628
  • Johnson & Johnson$626
  • E.r. Squibb & Sons, L.L.C.$517
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$1,30018%
  • Food & beverage$5,60478%
  • Education$3164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,220 in reported general payments places this provider in the 55th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$122,800
Medicare patients
437
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa47$1,005,024
Cosentyx Sensoready (2 Pens)Secukinumab62$617,778
Dupixent PenDupilumab129$489,790
Humira(Cf) PenAdalimumab52$432,416
OtezlaApremilast47$235,350
SotyktuDeucravacitinib13$92,291
Taltz AutoinjectorIxekizumab12$78,563
Dupixent SyringeDupilumab13$53,049
OpzeluraRuxolitinib Phosphate20$41,087
Clobetasol Propionate570$18,400
JubliaEfinaconazole11$13,449
Triamcinolone Acetonide795$9,461
Metronidazole82$7,268
Ketoconazole373$5,703
Hydroxyzine Hcl365$4,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$205$235,35047 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$517$92,29113 claims
Incyte CorporationOpzelura$246$41,08720 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$40$13,44911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →